Global Tumor NGS Genetic Testing Market Growth (Status and Outlook) 2025-2031

The global Tumor NGS Genetic Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Tumor NGS Genetic Testing is to use high-throughput sequencing to understand tumors at the genetic level, detect and quantify the genetic components that drive tumors.

United States market for Tumor NGS Genetic Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Tumor NGS Genetic Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Tumor NGS Genetic Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Tumor NGS Genetic Testing players cover Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Tumor NGS Genetic Testing Industry Forecast” looks at past sales and reviews total world Tumor NGS Genetic Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Tumor NGS Genetic Testing sales for 2025 through 2031. With Tumor NGS Genetic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor NGS Genetic Testing industry.

This Insight Report provides a comprehensive analysis of the global Tumor NGS Genetic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor NGS Genetic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor NGS Genetic Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor NGS Genetic Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor NGS Genetic Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor NGS Genetic Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:
Liquid Biopsy (Blood Sample)
Tissue Biopsy

Segmentation by Application:
Companion Diagnostics
Early Cancer Screening
Drug Discovery

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
Geneis（Beijing）Co.Ltd.
HaploX

Please note: The report will take approximately 2 business days to prepare and deliver. Show more